November 1, 2022 06:59 AM EDTUpdated 07:12 AM

Drew Armstrong is coming to Endpoints(!) And there are some more surprises to come

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN

TRENDING NOW

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

Corvus' early-phase atopic dermatitis data prompt stock rally

'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis

AI biotech Insilico Medicine goes for third attempt at Hong Kong IPO

GSK awaits Nucala decision after FDA target date passes

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges